Nuvalent: 'Hold' On GlaxoSmithKline Acquisition For Selective Tyrosine Kinase Inhibitors

GlaxoSmithKline is acquiring Nuvalent for $10.6 billion ($124 per share), capping upside and earning a 'Hold' rating. Nuvalent's selective TKIs neladalkib and zidesamtinib posted positive pivotal trial results in ALK-positive and ROS1-positive NSCLC, with NDAs submitted and 2026 PDUFA dates set.